Sustained-release antihistamine drugs that contain bepotastine besilate will be listed for reimbursement for the first time in Korea.

The original bepotastine besilate product developed by Mitsubishi Tanabe Pharma Corporation is Tarion. Tarion was sold by Dong-A ST in 2004 in Korea, and the company withdrew from the Korean market in December 2017 after the drug’s patent expired.

Therefore, only its generics that contain the same ingredients and salt-modified products are currently being sold in the Korean market.

According to industry sources on the 21st, 9 sustained-release antihistamine products will be listed for reimbursement at a ceiling price of KRW 326 from March